» Articles » PMID: 19783176

Outcomes of Children with Restrictive Cardiomyopathy Listed for Heart Transplant: a Multi-institutional Study

Overview
Publisher Elsevier
Date 2009 Sep 29
PMID 19783176
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Restrictive cardiomyopathy (RCM) in children often has a progressive nature, with a high risk of clinical deterioration and death. Heart transplantation (HTx) is a widely accepted therapy that offers long-term survival, but criteria for and outcomes after listing have not been well defined.

Methods: A multi-institutional, prospective, event-driven data registry of 3,147 patients aged < 18 years listed for HTx from January 1993 to December 2006 was used to assess risk factors and survival of 145 listed RCM patients.

Results: Mean age at listing was 8.1 years, with 44% listed as United Network of Organ Sharing status 1, 33% on inotropic support, 10% on a ventilator, and 5% on mechanical support. At 1 year, 82% of these patients survived to HTx, whereas 9% died waiting. Univariate risk factors for death while waiting included younger age (p < 0.001), ventilator dependence (p < 0.001), status 1 (p < 0.001), and inotrope usage (p < 0.001). Use of multiple support devices at listing (ventilator, extracorporeal membrane oxygenation, ventricular assist device, intraaortic balloon pump) was also an important risk factor for early phase death while waiting (relative risk; 9.01, p < 0.0001). Survival after listing was 63% at 10 years and compared favorably with survival for non-cardiomyopathy patients (p = 0.01).

Conclusions: Children with RCM awaiting HTx have a generally low waitlist mortality and reasonable overall survival. Children requiring mechanical support and infants had a significantly higher risk of death while waiting. Further study is warranted to identify factors important in determining the optimal timing of listing in children with RCM before the need for inotropic or mechanical support.

Citing Articles

Challenging of ECMO application in pediatric restrictive cardiomyopathy: case report of a novel variant.

Jin Y, Xu J, Hua Y, Zhang H, Li Y Front Cardiovasc Med. 2024; 11:1365209.

PMID: 38854656 PMC: 11157066. DOI: 10.3389/fcvm.2024.1365209.


Focus on Paediatric Restrictive Cardiomyopathy: Frequently Asked Questions.

Zampieri M, Di Filippo C, Zocchi C, Fico V, Golinelli C, Spaziani G Diagnostics (Basel). 2023; 13(24).

PMID: 38132249 PMC: 10742619. DOI: 10.3390/diagnostics13243666.


Symptomatic presentation influences outcomes in pediatric restrictive cardiomyopathy.

Lorenzo M, Lynch A, Ashkanase J, Fazari L, George K, Arathoon K Front Pediatr. 2023; 11:1264751.

PMID: 37928350 PMC: 10620919. DOI: 10.3389/fped.2023.1264751.


Pediatric Restrictive Cardiomyopathies.

Ditaranto R, Caponetti A, Ferrara V, Parisi V, Minnucci M, Chiti C Front Pediatr. 2022; 9:745365.

PMID: 35145940 PMC: 8822222. DOI: 10.3389/fped.2021.745365.


2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients.

Shah M, Silka M, Avari Silva J, Balaji S, Beach C, Benjamin M Indian Pacing Electrophysiol J. 2021; 21(6):367-393.

PMID: 34333141 PMC: 8577100. DOI: 10.1016/j.ipej.2021.07.005.